Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Discussion

@article{Heal1998SibutramineAN,
  title={Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Discussion},
  author={David J. Heal and Sue Aspley and Michael R. Prow and Helen C. Jackson and Keith F Martin and Sharon C. Cheetham},
  journal={International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity},
  year={1998},
  volume={22 Suppl 1},
  pages={S18-28; discussion S29}
}
Sibutramine (BTS 54 524; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate) is a novel 5-HT (serotonin) and noradrenaline reuptake inhibitor (SNRI) anti-obesity drug. Sibutramine reduces the food intake of rodents and this effect is partially or completely reversed by pretreating with 5-HT or noradrenaline antagonists, indicating that both neurotransmitters are involved in sibutramine's hypophagic effect. In addition, fluoxetine and nisoxetine, which… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 69 extracted citations

Similar Papers

Loading similar papers…